Can Fite Biofarma (Can Fite Biofarma) Market Cap

: $11.27 Mil (As of Today)

View and export this data going back to 2012. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Can Fite Biofarma's share price for the quarter that ended in Dec. 2023 was $2.2. Can Fite Biofarma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 4.53 Mil. Therefore, Can Fite Biofarma's market cap for the quarter that ended in Dec. 2023 was $9.97 Mil.

Can Fite Biofarma's quarterly market cap declined from Jun. 2023 ($12.53 Mil) to Sep. 2023 ($10.82 Mil) and declined from Sep. 2023 ($10.82 Mil) to Dec. 2023 ($9.97 Mil).

Can Fite Biofarma's annual market cap declined from Dec. 2021 ($35.08 Mil) to Dec. 2022 ($16.67 Mil) and declined from Dec. 2022 ($16.67 Mil) to Dec. 2023 ($9.97 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Can Fite Biofarma's Enterprise Value for Today is $2.23 Mil.

Can Fite Biofarma Market Cap Historical Data

The historical data trend for Can Fite Biofarma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

13.27

27.52

35.08

16.67

9.97

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap																16.67	9.35	12.53	10.82	9.97

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma Market Cap Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Market Cap distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Market Cap falls into.

Can Fite Biofarma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Can Fite Biofarma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$2.2	*	4.53279
	=	$9.97

Can Fite Biofarma's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$2.2	*	4.53279
	=	$9.97

Can Fite Biofarma (AMEX:CANF) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Can Fite Biofarma Market Cap Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).